Market Place
Sourcing Support
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA
06 Jul 2023 //
BUSINESSWIRE
Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal
13 Dec 2022 //
REUTERS
Sustained Patient Response to KRYSTEXXA® (pegloticase) Inj with Methotrexate
08 Nov 2022 //
BUSINESSWIRE
Data Support the Use of KRYSTEXXA with Methotrexate to Treat Uncontrolled Gout
05 Nov 2022 //
BUSINESSWIRE
Krystexxa plus methotrexate approved for uncontrolled gout
09 Jul 2022 //
FIERCEPHARMA
Horizon Pharma Pegloticase Receives Supplemental Approval in US
07 Jul 2022 //
FDA
KRYSTEXXA Plus Methotrexate Resulted in Improvement in Efficacy and Safety
01 Jun 2022 //
BUSINESSWIRE
FDA Grants Priority Review to Horizon Tx of sBLA for KRYSTEXXA Plus Methotrexate
07 Mar 2022 //
BUSINESSWIRE
Horizon Submits Supplemental Biologics License for KRYSTEXXA + Methotrexate
10 Jan 2022 //
BUSINESSWIRE
Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection)
04 Nov 2021 //
BUSINESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
01 Nov 2021 //
BIOSPACE
New Data Being Presented at American College of Rheumatology Convergence 2021
01 Nov 2021 //
BUSINESSWIRE
Horizon’s Krystexxa+methotrexate meets primary endpoint in trial
26 Oct 2021 //
CLINICALTRIALSARENA
Pegloticase Use for Uncontrolled Gout in the Dialysis Population Described
07 Apr 2021 //
RENALDUROLOGY
RECIPE Randomized Controlled Trial Data Published in Arthritis & Show
06 Apr 2021 //
BUSINESSWIRE
First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA®
25 Mar 2021 //
BUSINESSWIRE
Horizon Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020
11 Jan 2021 //
BUSINESSWIRE
Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA®
02 Nov 2020 //
PRESS RELEASE
Horizon Initiates Clinical Trial to Assess Shorter Infusion for KRYSTEXXA®
30 Oct 2020 //
BUSINESSWIRE
Horizon Initiates Clinical Trial to Assess Shorter Infusion for KRYSTEXXA®
29 Oct 2020 //
HORIZONTHERAPEUTICS
New Data Offers Insights on Treatment with KRYSTEXXA®
22 Oct 2020 //
BIOSPACE
New Data Evaluating KRYSTEXXA® (pegloticase injection) Immunomodulation
08 Oct 2020 //
BUSINESSWIRE
Target Enrollment Reached in MIRROR Randomized Controlled Trial KRYSTEXXA®
22 Jul 2020 //
BIOSPACE
Data Presented on KRYSTEXXA® Co-Prescribed with an Immunomodulator Adds
03 Jun 2020 //
BIOSPACE
Data on Multiple Immunomodulation Approaches with KRYSTEXXA® (pegloticase inj)
21 May 2020 //
YAHOO
MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA
13 Jan 2020 //
BUSINESSWIRE
Data from Uncontrolled Gout Case Series Supports Immunomodulation KRYSTEXXA®
11 Nov 2019 //
BUSINESSWIRE
Horizon Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection)
17 Oct 2019 //
BUSINESSWIRE
Horizon bulks up sales force ahead of $750M inflammatory eye drug launch
26 Jun 2019 //
FIERCE PHARMA
Horizon Pharma`s Clinical Trial to Evaluate pegloticase injection + Methotrexate
27 Sep 2018 //
BUSINESSWIRE
Horizon Reports Record Quarterly Net Sales for Orphan and Rheumatology Segment
08 Aug 2018 //
PRESS RELEASE
